利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

41 条记录 (耗时 0.032 秒)

    DETECTION OF FUNCTIONAL AUTOANTIBODIES
    2.
    发明申请
    DETECTION OF FUNCTIONAL AUTOANTIBODIES 审中-公开

    公开(公告)号：WO2020037378A1

    公开(公告)日：2020-02-27

    申请号：PCT/AU2019/050895

    申请日：2019-08-23

    申请人： THE FLINDERS UNIVERSITY OF SOUTH AUSTRALIA

    发明人： JACKSON, Michael, Warren

    IPC分类号： G01N33/564 ,  A61K49/00

    摘要： The present disclosure relates to methods for detecting functional autoantibodies and to diagnostic and prognostic applications of the methods. In certain embodiments, the present disclosure provides a method of detecting a functional autoantibody against an antigenic target, the method comprising exposing a cell expressing the antigenic target to the autoantibody, wherein the antigenic target has an activity to alter the level of reactive oxygen or nitrogen species in the cell and binding of the autoantibody to the antigenic target alters the activity of the antigenic target, and detecting the functional antibody on the basis of a change in the level of the reactive oxygen or nitrogen species in the cell.

    DIAGNOSTIC METHOD FOR DISEASES CHARACTERISED BY RO/LA AUTOIMMUNITY
    4.
    发明申请
    DIAGNOSTIC METHOD FOR DISEASES CHARACTERISED BY RO/LA AUTOIMMUNITY 审中-公开
    RO / LA自动识别诊断疾病诊断方法

    公开(公告)号：WO2013185181A1

    公开(公告)日：2013-12-19

    申请号：PCT/AU2013/000635

    申请日：2013-06-14

    申请人： CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC ,  THE FLINDERS UNIVERSITY OF SOUTH AUSTRALIA

    发明人： GORDON, Tom ,  ARENTZ, Georgia ,  LINDOP, Rhianna

    IPC分类号： G01N33/563 ,  G01N33/53 ,  G01N33/48 ,  A61K39/395

    CPC分类号： C07K16/18 ,  C07K2317/34 ,  G01N33/564 ,  G01N2800/101 ,  G01N2800/104 ,  G01N2800/24

    摘要： A method of detecting autoantibodies associated with Ro/La autoimmunity comprising detecting, in a serum sample or other sample comprising immunoglobulin G (IgG), autoantibodies to a Ro and/or La antigen comprising a variable (V)-region molecular signature comprising an unusual or common heavy (H) and light (L)-chain pairing and/or at least one mutation in one or more of said H- and L-chains and/or an adjacent region. The method enables the detection of autoantibodies associated with one or more autoimmune disease or disorder characterised by Ro/La autoimmunity such as Sjögren's syndrome (SS), systemic lupus erythematosus (SLE), neonatal lupus syndrome, other systemic rheumatic diseases, polymyositis, progressive systemic sclerosis, primary biliary cirrhosis and congenital heart block (CHB).

    摘要翻译： 检测与Ro / La自身免疫相关的自身抗体的方法，包括在包含免疫球蛋白G（IgG）的血清样品或其他样品中检测包含Ro和/或La抗原的自身抗体的方法，其包含可变（V） - 区域分子标记，其包含不寻常的 或H链和/或相邻区域中的一个或多个中的常规重（H）和轻（L）链配对和/或至少一个突变。 该方法能够检测与由一种或多种自身免疫性疾病相关的自身抗体的检测，所述自身免疫性疾病或疾病的特征在于诸如Sjögren综合征（SS），系统性红斑狼疮（SLE），新生儿狼疮综合征，其他全身性风湿病，多发性肌炎，进行性全身性系统性红斑狼疮 原发性胆汁性肝硬化和先天性心脏阻塞（CHB）。

    METHOD FOR IDENTIFYING A DIAGNOSTIC BIOMARKER FOR AN ANTIBODY OF INTEREST
    5.
    发明申请
    METHOD FOR IDENTIFYING A DIAGNOSTIC BIOMARKER FOR AN ANTIBODY OF INTEREST 审中-公开
    用于鉴定诊断抗生素的诊断生物标志物的方法

    公开(公告)号：WO2013185180A1

    公开(公告)日：2013-12-19

    申请号：PCT/AU2013/000634

    申请日：2013-06-14

    申请人： CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC. ,  THE FLINDERS UNIVERSITY OF SOUTH AUSTRALIA

    发明人： GORDON, Tom ,  ARENTZ, Georgia

    IPC分类号： G01N33/563 ,  G01N33/53 ,  G01N33/48

    CPC分类号： G01N33/564 ,  G01N33/6845 ,  G01N33/6854

    摘要： A method of identifying a detectable molecular signature for an antibody or antibodies of interest (eg autoantibodies associated with one or more autoimmune diseases) wherein the molecular signature comprises an Unusual or common heavy (H)-chain and light (L)-chain pairing and/or at least one mutation in one or more of said H- and L-chains and/or an adjacent region. The detection of antibodies comprising such a molecular signature, preferably by using a targeted mass spectroscopy (MS) approach to directly sequence the antibodies or a part(s) thereof, can provide a diagnostic biomarker for one or more disease or disorder.

    摘要翻译： 鉴定抗体或感兴趣的抗体（例如与一种或多种自身免疫疾病相关的自身抗体）的可检测分子特征的方法，其中分子特征包括不寻常的或常见的重（H）链和轻（L）链配对和 或者所述H链和L链中的一个或多个中的至少一个突变和/或相邻区域。 包含这种分子特征的抗体的检测优选通过使用靶向质谱法（MS）方法直接对抗体或其一部分进行序列测定，可为一种或多种疾病或病症提供诊断性生物标志物。

    OCULAR TISSUE MODIFICATION
    6.
    发明申请
    OCULAR TISSUE MODIFICATION 审中-公开
    眼科组织修改

    公开(公告)号：WO2005049092A1

    公开(公告)日：2005-06-02

    申请号：PCT/AU2004/001606

    申请日：2004-11-19

    申请人： THE FLINDERS UNIVERSITY OF SOUTH AUSTRALIA ,  JESSUP, Claire, F. ,  BRERETON, Helen, M. ,  COSTER, Douglas, J. ,  WILLIAMS, Keryn, A.

    发明人： JESSUP, Claire, F. ,  BRERETON, Helen, M. ,  COSTER, Douglas, J. ,  WILLIAMS, Keryn, A.

    IPC分类号： A61K48/00

    CPC分类号： A01K67/0271 ,  A01K2227/103 ,  A01K2267/03 ,  A61K35/30 ,  A61K38/00 ,  A61K38/208 ,  A61K48/005 ,  A61K48/0075 ,  C07K14/5428 ,  C12N15/86 ,  C12N2710/10343

    摘要： The present invention relates generally to the field of tissue modification, and in particular, but not exclusively, to methods of modifying cells of ocular and particularly corneal tissue to produce immunoglobulins or immunoglobulin fragments. The invention also relates to modified ocular cells and tissues, to expression vectors utilised in such methods, to methods of xeno- and allo-transplantion using the modified tissue and to methods of therapy of ocular diseases and disorders. In a preferred embodiment of the invention there is provided a method of modifying cells of ocular tissue to produce an immunoglobulin or immunoglobulin fragment of interest, which comprises exposing ocular tissue to an effective concentration for transfection of an expression vector comprising a nucleotide sequence encoding for the immunoglobulin or immunoglobulin fragment, for a period sufficient to allow transfection, such that cells of said ocular tissue produce the immunoglobulin or immunoglobulin fragment.

    摘要翻译： 本发明一般涉及组织修饰领域，特别是但并非排他地涉及修饰眼部和特别是角膜组织的细胞以产生免疫球蛋白或免疫球蛋白片段的方法。 本发明还涉及修饰的眼细胞和组织，用于这些方法中的表达载体，使用修饰组织的异种移植和同种异体移植的方法以及眼部疾病和病症的治疗方法。 在本发明的一个优选实施方案中，提供了一种修饰眼组织细胞以产生感兴趣的免疫球蛋白或免疫球蛋白片段的方法，其包括将眼组织暴露于有效浓度以转染表达载体，所述表达载体包含编码 免疫球蛋白或免疫球蛋白片段，持续足以允许转染的时间，使得所述眼组织的细胞产生免疫球蛋白或免疫球蛋白片段。

    ISOLATION OF FETAL CELLS FROM MATERNAL BLOOD TO ENABLE PRENATAL DIAGNOSIS
    7.
    发明申请
    ISOLATION OF FETAL CELLS FROM MATERNAL BLOOD TO ENABLE PRENATAL DIAGNOSIS 审中-公开
    从母体细胞中分离出阴道细胞以达到预期的诊断

    公开(公告)号：WO1990006509A1

    公开(公告)日：1990-06-14

    申请号：PCT/AU1989000517

    申请日：1989-11-29

    申请人： THE FLINDERS UNIVERSITY OF SOUTH AUSTRALIA ,  MUELLER, Utz, Walter ,  HAWES, Catherine, Stezia

    发明人： THE FLINDERS UNIVERSITY OF SOUTH AUSTRALIA

    IPC分类号： G01N33/53

    CPC分类号： C07K16/18 ,  C07K14/4715 ,  G01N33/56966 ,  G01N33/689 ,  G01N2800/368 ,  Y10S435/968

    摘要： This invention relates to a method for the isolation of trophoblast (placental) cells from the blood of a pregnant mammal so as to provide the essential starting material, namely cells derived from the fetus, to enable genetic and/or biochemical information about the fetus to be obtained. In particular, this invention relates to the use of monoclonal antibodies specific for membrane protein markers on mammalian trophoblasts to isolate trophoblast cells from maternal blood. These cells may then be used to obtain fetal genetic and/or biochemical information early in pregnancy. The present invention is particularly relevant for detecting human fetal abnormalities.

    摘要翻译： 本发明涉及一种从怀孕哺乳动物的血液中分离滋养细胞（胎盘）细胞的方法，以便提供必要的起始物质，即来自胎儿的细胞，以使关于胎儿的遗传和/或生化信息能够 得到。 特别地，本发明涉及在哺乳动物滋养层上分离滋养层细胞从母体血液中分离膜蛋白标记特异性的单克隆抗体。 然后可以将这些细胞用于在怀孕早期获得胎儿遗传和/或生化信息。 本发明特别适用于检测人类胎儿异常。

    METHOD FOR ENHANCING EMBRYO IMPLANTATION
    8.
    发明申请
    METHOD FOR ENHANCING EMBRYO IMPLANTATION 审中-公开

    公开(公告)号：WO2019227122A1

    公开(公告)日：2019-12-05

    申请号：PCT/AU2019/000067

    申请日：2019-05-29

    申请人： THE FLINDERS UNIVERSITY OF SOUTH AUSTRALIA ,  THE UNIVERSITY OF MELBOURNE

    发明人： TREMELLEN, Kelton Paul ,  GARDNER, David K. ,  HARVEY, Alexandra J.

    IPC分类号： A61K33/34 ,  A61K33/26 ,  A61P15/08 ,  A61P41/00 ,  A61B17/435 ,  A61F6/14

    摘要： A method of enhancing embryo implantation in a subject is disclosed which comprises administering to the uterine cavity of the subject a formulation comprising copper and/or zinc in an amount effective to stimulate endometrial production of leukaemia inhibitory factor (LTF) and' or vascular endothelial growth factor ( VEGF). Alternatively, a device may be inserted into the uterine cavity of the subject, wherein the device comprises copper and/or zinc, for a period of time that is effective to stimulate endometrial production of LIF and/or VEGF. The method is suitable for use with women undergoing treatment by any of the assisted reproductive technologies, such as those involving the transfer of embryos such as in vitro fertilisation (IVF) and variants including IVF-ICSI (intracytoplasmic spenn injection) and m vitro maturation (1VM) treatments, as well as intrauterine-insemination (IUI) therapy. However, the method is also applicable for women wanting to improve their prospects of pregnancy through natural conception.